Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Limited has issued 22,846,154 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with the company’s strategic efforts to enhance its financial standing and support ongoing negotiations with Hong Kong distributors. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, indicating compliance with regulatory requirements. This capital injection is expected to bolster Orthocell’s operations and potentially strengthen its position in the regenerative medicine industry.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for tissue reconstruction and healing, as well as autologous cell therapies aimed at regenerating damaged tendon and cartilage tissue. The company is expanding its market presence with products like Striate+™ for dental applications and Remplir™ for nerve reconstruction, which have received approvals in multiple countries.
Average Trading Volume: 628,709
Technical Sentiment Signal: Buy
Current Market Cap: A$323.7M
See more insights into OCC stock on TipRanks’ Stock Analysis page.